Citrus bergamia Risso et Poiteau · supplement
Evidence tier: limited
A natural lipid modulating polyphenol, works via the same pathway as statins but more gently.
The bergamot polyphenolic fraction, principally brutieridin and melitidin, carries a side chain structurally resembling statins, and in laboratory systems it inhibits HMG CoA reductase and activates AMPK. This is a genuinely interesting structural story and it is the best reason to believe the LDL direction is real rather than noise. It is however a preclinical mechanism, demonstrated in cells and animals, not proven to be the operating mechanism at the doses people take.
Limited, and the reason is a lesson in reading meta analyses sceptically. The headline number looks spectacular. A 2022 systematic review and meta analysis in Phytotherapy Research (14 randomised trials) reports that bergamot lowered total cholesterol by 63.6 mg per dL, LDL by 55.4 mg per dL and triglycerides by 74.7 mg per dL, and raised HDL by 5.8 mg per dL. An LDL reduction of 55 mg per dL is roughly what a moderate intensity STATIN achieves. A citrus polyphenol extract producing a statin sized effect, from a small trial base, is not a reason for confidence; it is a red flag that the trial base is unreliable. And it is. The trials are small, heavily concentrated in a single research community in Calabria in southern Italy where bergamot is the regional crop, frequently connected to the producers of the extract, and methodologically uneven. Reviewers themselves note that extraction, preparation and standardisation differed from one trial to another, that some trials used an OPEN LABEL design or ran as prospective studies with no placebo control, and that the effects on HDL and triglycerides are inconsistent across studies. Heterogeneity is high. No independent, adequately powered, multi centre replication exists. So there is a real and repeatedly observed direction of effect on LDL, which is why this is not graded insufficient, but the magnitude is not credible and the evidence base is not independent, which is why it is not graded moderate. SEPARATE PRODUCT WARNING: bergamot ESSENTIAL OIL is not the fruit extract. It contains bergapten, a furocoumarin, and is PHOTOTOXIC, capable of causing severe phototoxic burns and hyperpigmentation on sun exposed skin. Reviewers note explicitly that given the known phototoxicity of bergapten it is not a prime candidate for use as a cholesterol lowering agent. The oral polyphenol fraction and the essential oil must never be conflated.
500 to 1,000 mg daily of a standardised bergamot polyphenolic fraction, which is the band used across most of the trials, typically with the evening meal. No regulator establishes a dose because no regulator has recognised the indication.
500 to 1000 mg standardised BPF daily, with the evening meal.
Onset: ~30 days
May interact with statins (synergistic, clinical supervision recommended) and CYP3A4 substrates.
Pregnancy: caution
Breastfeeding: caution
Active compounds: brutieridin, melitidin, neoeriocitrin, neohesperidin, naringin
Remedies using Bergamot · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.